NorthSea Therapeutics

NorthSea Therapeutics: First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. Lead candidate Icosabutate for NASH; positive Ph 2b interim data announced Jan. 21 shows highly statistically significant reductions in major biomarkers impacting NASH resolution and fibrosis. Pipeline includes SEFA-1024 (Ph1, dyslipidemia) and late-stage preclinical Parenteral Nutrition Associated Liver Disease (PNALD) program. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments - funds completion of Ph 2b ICONA study in NASH.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Other
Clinical Stage
Phase l or ll
Finance
Pre-earnings
Industry
Biotechnology
Investment Participation
CrossOvers
Listing
Private
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
Gooimeer 2 35
Naarden, Noord-Holland 1411 DC
The Netherlands

Company Participants at European Biotech Investor Days 2021

Rob de Ree
NorthSea Therapeutics, Chief Executive Officer & Board Member
Prior to joining NorthSea Therapeutics B.V., Rob de Ree served as the CEO of the start-up companies Dezima Pharma, which was acquired by Amgen in 2015 and as the CEO of BMEYE which was acquired by Edwards lifesciences in 2012. Before that Rob de Ree served as the head of the licensing business of Crucell and in various national and international sales and marketing roles at Medtronic. Rob de Ree started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden in the Netherlands. In addition Rob de Ree is currently a board member at Ventinova (chair) and Mellon medical and operating partner at Biogeneration Ventures. Rob de Ree holds an MSc in pharmacy from the University of Groningen.

Upcoming Company Event Participation